Stratos Wealth Partners LTD. Sells 4,014 Shares of Organon & Co. $OGN

Stratos Wealth Partners LTD. lowered its stake in Organon & Co. (NYSE:OGN) by 18.3% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 17,861 shares of the company’s stock after selling 4,014 shares during the quarter. Stratos Wealth Partners LTD.’s holdings in Organon & Co. were worth $173,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Hanson & Doremus Investment Management bought a new position in shares of Organon & Co. during the second quarter worth $26,000. Ransom Advisory Ltd bought a new stake in Organon & Co. during the 1st quarter worth about $32,000. Brooklyn Investment Group lifted its position in Organon & Co. by 1,012.3% during the 1st quarter. Brooklyn Investment Group now owns 3,070 shares of the company’s stock worth $46,000 after buying an additional 2,794 shares in the last quarter. Ridgewood Investments LLC bought a new stake in Organon & Co. during the 2nd quarter worth about $48,000. Finally, BI Asset Management Fondsmaeglerselskab A S bought a new stake in Organon & Co. during the 1st quarter worth about $51,000. Institutional investors and hedge funds own 77.43% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (d+)” rating on shares of Organon & Co. in a research report on Saturday. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $17.33.

Organon & Co. Trading Up 1.3%

Organon & Co. stock opened at $9.17 on Monday. Organon & Co. has a 52 week low of $8.01 and a 52 week high of $19.05. The company has a debt-to-equity ratio of 11.98, a quick ratio of 1.13 and a current ratio of 1.65. The stock has a market capitalization of $2.38 billion, a P/E ratio of 3.41, a PEG ratio of 0.83 and a beta of 0.63. The stock has a 50-day simple moving average of $9.92 and a 200 day simple moving average of $9.88.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $1.00 EPS for the quarter, topping analysts’ consensus estimates of $0.94 by $0.06. Organon & Co. had a return on equity of 163.88% and a net margin of 11.15%.The business had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $1.55 billion. During the same quarter last year, the company posted $1.12 earnings per share. Organon & Co.’s quarterly revenue was down .8% on a year-over-year basis. Organon & Co. has set its FY 2025 guidance at EPS. Analysts expect that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, September 11th. Investors of record on Friday, August 15th were paid a $0.02 dividend. The ex-dividend date was Friday, August 15th. This represents a $0.08 dividend on an annualized basis and a yield of 0.9%. Organon & Co.’s dividend payout ratio is 2.97%.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.